Search research articles
Contact Us
Filters
Showing results (1-10 of 7) with videos related to
Page
of 1
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 6, 2003
Cost-effectiveness studies in ovarian cancer
T D Szucs, P Wyss, K J Dedes
Breast Cancer Research and Treatment
|
June 10, 2016
Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK)
K Matter-Walstra, T Ruhstaller, D Klingbiel, et al.
Archives of Gynecology and Obstetrics
|
November 26, 2011
Inpatient and outpatient loop electrosurgery excision procedure for cervical intraepithelial neoplasia: a retrospective analysis
B Leimbacher, N Samartzis, P Imesch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 1, 2007
Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial
K J Dedes, T D Szucs, P Imesch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 7, 2010
Trastuzumab beyond progression: a cost-utility analysis
K W Matter-Walstra, K J Dedes, M Schwenkglenks, et al.
Oral Oncology
|
December 12, 2018
Cost-effectiveness of nivolumab in the treatment of head and neck cancer
A Hirschmann, J E Lupatsch, M Schwenkglenks, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 29, 2020
A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland
C M Panje, J E Lupatsch, M Barbier, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 7) with videos related to
Sort By:
Page
of 1
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 6, 2003
Cost-effectiveness studies in ovarian cancer
T D Szucs, P Wyss, K J Dedes
Breast Cancer Research and Treatment
|
June 10, 2016
Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK)
K Matter-Walstra, T Ruhstaller, D Klingbiel, et al.
Archives of Gynecology and Obstetrics
|
November 26, 2011
Inpatient and outpatient loop electrosurgery excision procedure for cervical intraepithelial neoplasia: a retrospective analysis
B Leimbacher, N Samartzis, P Imesch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 1, 2007
Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial
K J Dedes, T D Szucs, P Imesch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 7, 2010
Trastuzumab beyond progression: a cost-utility analysis
K W Matter-Walstra, K J Dedes, M Schwenkglenks, et al.
Oral Oncology
|
December 12, 2018
Cost-effectiveness of nivolumab in the treatment of head and neck cancer
A Hirschmann, J E Lupatsch, M Schwenkglenks, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 29, 2020
A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland
C M Panje, J E Lupatsch, M Barbier, et al.
Page
of 1